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Background: Is it well-known that one of the major drawbacks of Lupus Anticoagulant
(LA) test is their sensitivity to anticoagulant therapy, due to the coagulation based
principle. In this study we aimed to assess the reproducibility of LA testing and to evaluate
the performance of solid assay phosphatidylserine/prothrombin (aPS/PT) antibodies.
Methods: We included 60 patients that fulfilled the following inclusion criteria: (I)
diagnosis of thrombotic antiphospholipid syndrome (APS); (II) patients with thrombosis
and (a) inconstant previous LA positivity and/or (b) positivity for antiphospholipid
antibodies (aPL) at low-medium titers [defined as levels of anti-β2Glycoprotein-I or
anticardiolipin (IgG/IgM) 10–30 GPL/MPL] with no previous evidence of LA positivity.
aPL testing was performed blindly in 4 centers undertaking periodic external quality
assessment.
Results: The 60 patients enrolled were distributed as follows: 43 (71.7%) with
thrombotic APS, 7 (11.7%) with thrombosis and inconstant LA positivity and 10 (16.7%)
with low-medium aPL titers. Categorical agreement for LA among the centers ranged
from 0.41 to 0.60 (Cohen’s kappa coefficient; moderate agreement). The correlation
determined at the 4 sites for aPS/PT was strong, both quantitatively (Spearman rho
0.84) and when dichotomized (Cohen’s kappa coefficients= 0.81 to 1.0). Discordant (as
defined by lack of agreement in≥3 laboratories) or inconclusive LA results were observed
in 27/60 (45%) cases; when limiting the analysis to those receiving vitamin K antagonist
(VKA), the level of discordant LA results was as high as 75%(15/20). Conversely, aPS/PT
testing showed an overall agreement of 83% (up to 90% in patients receiving VKA),
providing an overall increase in test reproducibility of +28% when compared to LA,
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becoming evenmore evident (+65%) when analyzing patients on VKA. In patients treated
with VKA, we observed a good correlation for aPS/PT IgG testing (Cohen’s kappa
coefficients = 0.81–1; Spearman rho 0.86).
Conclusion: Despite the progress in the standardization of aPL testing, we observed
up to 45% of overall discrepant results for LA, even higher in patients on VKA. The
introduction of aPS/PT testing might represent a further diagnostic tool, especially when
LA testing is not available or the results are uncertain.
Keywords: antiphosphospholipid syndrome, Antiphospholipid Antibodies, Lupus Anticoagulant, aPS/PT,
thrombosis, laboratory, diagnostic performance, reliability
INTRODUCTION
Since clinical features of Antiphospholipid Syndrome (APS)
(thrombosis and pregnancy complications) are common in the
general population and often related to other underlying factors,
the diagnosis of APS requires next to clinical assessment the
detection of persistently positive Antiphospholipid Antibodies
(aPL). Thus, reliable laboratory tests with good clinical and
analytical performance reproducibility are required. There is a
large variety of assays available to assess aPL, but despite progress,
standardization is still not optimal (1–3).
Lupus anticoagulant (LA) has been shown to be the strongest
risk factor for aPL-related clinical manifestations (4), and the
correct interpretation of this functional assay is crucial for
diagnosis of APS. However, testing patients during treatment
with vitamin K antagonists (VKA) or other oral anticoagulants
remains a contentious issue and has been discouraged by official
guidelines (5–7) because of interpretational problems affecting
the mixing test. Besides, the clinical significance of low aPL titer
and/or weak LA positivity, especially when detected in patients
receiving anticoagulation [either VKA or direct anticoagulant
agents (DOAC)], remains uncertain and certainly needs a more
thorough evaluation.
More recently, the family of aPL has been expanded to include
a heterogeneous group of autoantibodies whose specificity is
directed to proteins involved in coagulation or to a complex
of these proteins with phospholipids (8). Among others,
autoantibodies that recognize a phosphatidylserine/prothrombin
(aPS/PT) complex have been reported to be associated with APS
and may have diagnostic relevance in these settings (9, 10).
However, since aPS/PT antibodies are not currently included in
the current APS classification criteria (11), aPS/PT antibodies
are not assessed in all patients suspected to suffer from APS.
Given the importance of aPL confirmation to improve the
interpretability of laboratory test results for clinical trials and
research studies, the objective of this study was to assess
the reproducibility of LA and aPS/PT antibody testing when
performed in different expert centers and to assess the diagnostic
performance of these tests in different clinical settings of APS.
METHODS
Patients
We chart-reviewed patients with thrombotic events who tested
persistently positive for at least one aPL (more than two occasions
over a time of more than 12 weeks) that presented at San
Giovanni Bosco Hospital in the last 5 years. The study was
performed in compliance with the Declaration of Helsinki;
approval from the ethic committee was not required according
to the local and national guidelines. We enrolled 60 patients who
met one of the following inclusion criteria:
1) Fulfilled the diagnosis of thrombotic APS defined as per
Sydney criteria (11).
2) Patients with thrombosis and suspected APS not completely
fulfilling the laboratory criteria (11), as follows: (a)
inconsistent previous LA positivity; and/or (b) low-medium
aPL titers [defined as levels of anticardiolipin (aCL) IgG/IgM
or anti-β2-glycoprotein I (aβ2GPI) IgG/IgM antibodies 10–30
GPL/MPL]. Clinical and laboratory characteristics were
retrospectively collected.
Previous Autoantibody Detection
The aPL profile, at the diagnosis, included aCL, LA, and
aβ2GPI antibodies.
The aCL and aß2GPI (IgG and IgM) were detected by
commercial ELISA (Inova Diagnostics, Inc., San Diego, CA, US).
Plasma samples were tested for the presence of LA according
to the recommended criteria from the International Society on
Thrombosis and Haemostasis (ISTH) Subcommittee on Lupus
Anticoagulant/Phospholipid-Dependent Antibodies (12, 13).
Study Design
LA and aPS/PT testing was performed in a blind fashion
in four centers of the “Antiphospholipid Antibodies Regional
Consortium” in northwest Italy: San Giovanni Bosco Hospital,
Turin, Italy, A.O.U. Città della Salute e della Scienza, Turin, Italy,
A.O. OrdineMauriziano, Turin, Italy, and A.O.U.Maggiore della
Carità, Novara, Italy (14).
LA was tested with the detection of two different reagents,
used as screening and confirmatory tests, Silica Clotting
Time HemosIL and dRVVT Screen and Confirm HemosIL,
respectively (Instrumentation Laboratory, Bedford, MA, USA).
Both tests were automated on ACL TOP 750 LAS instruments
and results were normalized by means of plasma pools obtained
from healthy donors without any deficit in coagulation factors,
as per the current criteria from the ISTH Subcommittee on
LA-Phospholipid-dependent antibodies (12, 13).
Both IgG and IgM aPS/PT were assayed using commercial
ELISA kits (QUANTA Lite R©, Inova Diagnostic), in accordance
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with manufacturer’s instructions. Samples were considered
positive for aPS/PT IgG/IgM if tested>30 U.
Agreement was defined when all four laboratories had a
concordant binomial result (positive/negative), both for LA and
aPS/PT IgG/IgM testing.
Statistical Analysis
Categorical variables are presented as number (%) and
continuous variables are presented as mean (S.D.). Categorical
agreement and degree of linear association was analyzed. The
significance of baseline differences was determined by the
chi-squared test, Fisher’s exact test or the unpaired t-test,
as appropriate. A two-sided p-value < 0.05 was statistically
significant. All statistical analyses were performed using SPSS
version 19.0 (IBM, Armonk, NY, USA).
RESULTS
Demographic, clinical and laboratory characteristics of the 60
patients enrolled in the study are summarized in Table 1.
Briefly, mean age at data collection was 49.9 years old (SD
± 10.9) (females: males = 71.7%: 28.3%). Forty-three patients
(71.7%) had a confirmed diagnosis of thrombotic APS (arterial
58.1%; venous 56.3%), and 17 patients presented with thrombosis
and inconsistent LA positivity [7/17 (41.2%)] and/or with low-
medium titers [10/17(58.8%)]. In the latest, 10/17 patients with
suspected APS were tested positive (titer > 30 UI) for aPS/PT,
IgG and/or IgM.
TABLE 1 | Characteristics of the patients included in the study.
APS patients
(43; 72%)
Suspected
APS (17; 28%)
ANAGRAPHIC
Mean age (±S.D.) at
data collection
45.7 (±11.9) 51.9 (±7.3)
Females 30 (69.8%) 11 (64.7%)
CLINICAL MANIFESTATIONS
Arterial thrombosis 21 (48.8%) 5 (29.4%)
Venous thrombosis 26 (60.5%) 12 (70.6%)
aPL PROFILE AT DIAGNOSIS
LA (positive, n)* 37 (86%) 11 (64.7%)
aCL (IgG/M)* 22 (51.2%) 7 (41.2%)
aβ2GPI (IgG/M)* 23(53.5%) 6 (35.3%)
ANTICOAGULANT THERAPY AT THE MOMENT OF TESTING
VKA (warfarin) 18 (41.9%) 2 (11.8%)
LMWH 8 (18.6%) 2 (11.8%)
DOAC 13 (30.2%) 0
Anti-platelets therapy 17 (39.5%) 13 (76.5%)
SD, Standard Deviation; APS, Antiphospholipid Syndrome; aPL, Antiphospholipid
Antibodies; LA, Lupus Anticoagulant; aCL, Anticardiolipin Antibodies; anti-β2GPI, Anti-
β2Glycoprotein I antibodies; VKA, Vitamin K antagonists; LMWH, Low Molecular Weight
Heparins; DOAC, Direct Anticoagulants. *When considering patients with suspected APS:
defined as inconsistent LA positivity and/or low levels of ACA IgG/IgM or anti-β2GPI
IgG/IgM antibodies 10–30 GPL/MPL.
Overall, categorical agreement for LA among all the four
centers, as expressed by Cohen’s kappa coefficients, ranged
from 0.41 to 0.60 (corresponding to moderate agreement). The
correlation among quantitative results for aPS/PT IgG/IgM was
strong (Spearman rho 0.84; when dichotomizing for positive vs.
negative results, Cohen’s kappa coefficients= 0.81–1.00).
Overall categorical agreement is resumed in Figure 1.
We observed 27 (45.0% of the total) cases (15/20, 75% patients
on VKA) in which LA results were discordant (defined by lack
of agreement) or inconclusive. Conversely, in those cases, we
observed a good correlation for aPS/PT IgG/IgM testing (Cohen’s
kappa coefficients= 0.81–1.00, Spearman rho 0.86).
When considering previous LA testing, we observed a
statistically significant higher agreement among centers of LA
testing if LA testing was previously positive [LA previously
positive testing vs. negative: full agreement among centers 74.5%
vs. 30.7% (chi Square test p < 0.05)]. Interestingly, the level
of agreement of aPS/PT IgG/IgM among centers was similar
regardless of previous LA testing [LA previously positive vs.
negative: full agreement among centers 85.1% vs. 92.3% (chi
Square test p= 0.49)].
When stratifying patients according to the inclusion criteria,
we observed that in patients with confirmed diagnosis of APS,
LA, and aPS/PT (IgG/IgM) agreements were 24/43 (55.8%)
and 40/43 (93.0%), respectively. Conversely, in patients with
thrombosis not completely fulfilling the Sydney laboratory
criteria, we found aPL testing agreement among the four centers
as follows: LA 9/17 (52.9%) and aPS/PT IgG/IgM 11/17 (64.7%).
DISCUSSION
The diagnosis and consequent management as well as the
classification of APS relies on the identification of persistent
aPL positivity in patients with thrombosis and/or pregnancy
morbidity (11). Among aPL tests, LA has been shown to
be the strongest risk factor for thrombotic events (15) and
LA testing should always be performed in parallel with
aCL and aβ2GPI (3, 16–18) when a patients is investigated
for APS.
However, despite significant progress in LA testing thanks to
the updated guidelines of the ISTH (12, 13), LA testing still suffers
from some shortcomings and remain much more labor intensive
and complicated to perform compared to immunoassays.
In our study, when testing for LA in a blind fashion in four
centers all undergoing regular external quality assessment (EQA)
(14), we observed that up to 45% of LA positive samples were not
unanimously identified. When limiting the analysis to patients
with VKA, the observed level of agreement dropped to 55%.
Is it well-known that one of the major drawbacks of LA tests
is their sensitivity to anticoagulant therapy (such as VKA, and
DOAC), due to the coagulation based principle. Preferably, tests
should be postponed until therapy is stopped; however, in the
real world, requests during therapy still occur very frequently
with potentially false-positive or false-negative results (13, 19).
In addition, it might be logistical inconvenient for the patients to
switch (or stop) anticoagulant therapy for LA testing purpose.
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FIGURE 1 | Results of lupus anticoagulant (LA) and anti-PS/PT antibody obtained in four laboratories. Results are summarized for all the patients included in the study
(Left) and for patients with suspected APS (Right).
When a thrombotic event occurs in patients suspected for
APS with inconsistent LA positivity and/or with low-medium
aPL titers, clinical management can be challenging, as no
consensus exists on the choice and, more critically, the duration
of anticoagulation in this setting. In this study, when analyzing
patients not completely fulfilling the criteria for APS, we observed
a level of LA agreement of only 53%, supporting the need of
further diagnostic tool to help physicians in the management of
these patients.
Autoantibodies directed toward PS/PT complexes have been
extensively studied for their diagnostic and prognostic utility in
patients with suspected APS (9). Due to the observation that anti-
prothrombin antibodies associate significantly with LA (20–24),
several studies have sought to define the diagnostic relevance of
these antibodies in APS (9, 23, 25, 26). Recent evidence support
that while aPS/PT are frequently found in patients with LA,
their association with thrombosis seems to be independent of the
presence of LA (27).
Among the so-called extra-criteria aPL tests, besides aPS/PT,
antiβ2GPI-domain1 antibodies have been also proposed to
potentially improve the diagnostic accuracy in patients with
suspected APS (28, 29), especially when assessing the risk for
both thrombosis and pregnancy morbidity. Other antibody
specificities, such as anti-annexin A5 and anti-vimentin
antibodies, might be considered for thrombotic risk assessment
only in selected patients, particularly when other aPL tests are
negative and in the presence of clinical signs and/or symptoms
strongly suggestive for APS (26, 30).
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In our cohort, aPS/PT testing showed an overall agreement of
83% (up to 90% in patients receiving VKA), providing an overall
increase in test reproducibility of +28% when compared to LA,
becoming even more evident (+65%) when analyzing patients
on VKA. These observations have important implications. On
the one hand, LA testing remains a cornerstone for APS
diagnosis. On the other, ongoing efforts to reduce the LA
testing interlaboratory/interassay variations remain important.
Taking into account the methodological shortcomings of LA,
aPS/PT might represent a reliable and reproducible test, even
during VKA or when APS diagnosis in uncertain. Besides the
diagnosis, these findings also might have significant implications
for classification criteria and therefore for clinical trials of
new treatments.
Besides, albeit investigating the impact of aPS/PT testing
on the management of patients with suspected APS was
out of the scope of this study, one might note that up to
nearly 60% of the patients with suspected APS were found
positive for aPS/PT. From a speculative point of view, this
observation might support a role for aPS/PT testing when APS
is suspected but currently classification criteria aPL are not
fully informative/reliable.
Although our investigation suffers for some limitations (cross-
sectional approach limiting the analysis of the longitudinal
fluctuation in aPL positivity; limited sample size; no further
analysis on the level of agreement for aCL and aβ2GPI), the
strengths of this study relies on the blind approach of aPL
testing, performed in four different centers all undergoing
periodic EQA. Besides, in this investigation, we evaluated the
robustness of aPS/PT ELISA testing in different clinical settings,
including patients suspected for APS but tested negative/low-
titers for aCL and aβ2GPI antibodies. In such cases, a
further diagnostic tool for APS with reliable performances
might be crucial to guide the diagnostic process and to
avoid under/over treatment (31). Finally, testing for aPS/PT
by a commercial kit was proven to be a reproducible and
accurate test for the detection of aPS/PT, bringing the added
advantage of shorter running times when compared to in-house
assays (32).
In conclusion, despite the progress in the standardization of
aPL testing, we observed up to 45% of overall discrepant results
for LA, even higher in patients onVKA.Our findings showed that
the persistence of significant discordance in the reliability of LA
testing. The introduction of aPS/PT antibodies in the diagnostic
process of APS might represent a further valuable diagnostic
tool, especially when LA is not available or reliable. In addition,
detection of aPS/PT antibodies provides another tool which can
complement and support current testing with aCL and aβ2GPI
assays, and further help guiding clinical management.
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